At Aerami Therapeutics, we leverage our proprietary inhalation technology to develop differentiated inhaled therapies for the treatment of cardiopulmonary and cardiometabolic conditions.
A drug-device combination product candidate in Phase 1 for the treatment of pulmonary arterial hypertension
An inhaled glucagon-like peptide-1 (GLP-1) analog for the treatment of post-prandial hyperglycemia associated with Type 2 diabetes
A soft mist inhaled human insulin to improve glycemic control in Type 1 and Type 2 diabetes
Aerami Therapeutics is a clinical stage biopharmaceutical company engaged in the development of differentiated inhaled therapies for the treatment of cardiopulmonary and cardiometabolic conditions.
Sign up today and receive company updates straight to your inbox.